Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Keratosis, Actinic 5Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 2Papillomavirus Infections 2Melanoma 2Hemangioma, Capillary 2Breast Neoplasms 2Vulvar Neoplasms 1Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) 1Virus Diseases 1Vaginal Neoplasms 1Urinary Bladder Neoplasms 1Skin Neoplasms 1Sexually Transmitted Diseases 1Precancerous Conditions 1Pigmentation Disorders 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hemangioma 1HPV 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Basal Cell 1Carcinoma in Situ 1

Interventions

dodecyl maltoside 2toripalimab 1pembrolizumab 1durvalumab 1apaziquone 1Mitomycin 1Imiquimod 1Gemcitabine 1Docetaxel 1Cystoscopy 1Biopsy 1BCG Vaccine 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma in Situ × Imiquimod × Clear all
NCT01731652 2015-02-10

Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer

Telormedix SA

Phase 2 Completed
12 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡